



Highlights from:

Nils Perrin, MD, Cameron McAlister, MD, Michael Tsang, MD, Blandine Mondésert, MD, Réda Ibrahim MD, Jaqueline Saw, MD Perrin et al., Catheter Cardiovasc Interv, Nov 2022 DOI: 10.1002/ccd.30503

Boston Scientific
Advancing science for life™

Procedural simplification of left atrial appendage occlusion using the VersaCross connect system: First in-human experience

HIGHLIGHTS

- ▶ First in-human experience using the **VersaCross Connect™** LAAC Access Solution for **WATCHMAN FLX™** implantation was successful in all patients with no procedural complications.
- ▶ **VersaCross Connect™** improved procedure efficiency and saved six steps compared to the standard needle-based workflow.

INTRODUCTION

- ▶ Left atrial appendage closures (LAAC) traditionally require several device exchanges from transseptal puncture (TSP) to device delivery.
- ▶ The new **VersaCross Connect™** LAAC Access Solution (Baylis Medical*) is designed to integrate with the **WATCHMAN FLX™** delivery sheath (Boston Scientific) to access the left atrium (LA).
- ▶ This study reports the first in-human experience using the **VersaCross Connect™** LAAC Access Solution.

METHODS

- ▶ Prospective case series using the **VersaCross Connect™** system for **WATCHMAN FLX™** LAAC device at two different centers.
- ▶ Preprocedural planning involved cardiac computed tomography for all patients and all LAAC procedures were guided by transesophageal echocardiography (TEE).
- ▶ After vascular access, the **VersaCross Connect™** system, comprised of the **VersaCross™** RF Wire and the **VersaCross Connect™** dilator, was used in conjunction with the **WATCHMAN** sheath to cannulate the superior vena cava (SVC), and perform infero-posterior TSP to access the LA (Figure 1).
- ▶ The **WATCHMAN** sheath was placed in the left atrial appendage (LAA) over the pigtail **VersaCross™** RF Wire for **WATCHMAN FLX™** device placement.

RESULTS

- ▶ Nine consecutive cases of **WATCHMAN FLX™** LAAC were performed using the **VersaCross Connect™** system.
- ▶ LAAC was successful in 100% of patients with no procedural complications.
 - Time from TSP to **WATCHMAN FLX™** release was 12.2 ± 1.9 min.
 - Overall procedure time was 31 ± 6.3 min.
 - Fluoroscopy time was 6.7 ± 4.9 min.
- ▶ The **VersaCross Connect™** system was directly inserted into the right femoral vein in all but one patient.




Figure 1. VersaCross Connect™ LAAC Access Solution (Baylis Medical*) eliminates six steps from **WATCHMAN FLX™** (Boston Scientific) LAAC procedures compared to standard needle workflow. LA: left atria. LAAC: left atrial appendage closure. RF: radiofrequency. SVC: superior vena cava. TSP: transseptal puncture

DISCUSSION & CONCLUSIONS

- ▶ Streamlining LA access and simplifying LAAC procedures by eliminating multiple sheath exchanges can reduce the risk of air embolism and perforation.
- ▶ Short overall procedure time (31 min) and interval between LAA access and device deployment (12 min) were observed with the **VersaCross Connect™** Access Solution system.
- ▶ The **VersaCross Connect™** LAAC Access Solution allowed for safer and more efficient **WATCHMAN FLX™** LAAC procedures.

All trademarks are property of their respective owners. Patents Pending and/or issued.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, Contraindications, Warnings, and Instructions For Use can be found in the product labelling supplied with each device or at www.baylismedical.com.

Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries.

This material not intended for use in France.

Boston Scientific is a Global Company. Please note that model numbers, indications, contraindications, warnings and specifications may differ depending on geographic region. Not all information displayed in this brochure may be licensed in accordance with Canadian law. Please contact your Boston Scientific representative for local labeling, product specifications and licensed model numbers.

**Boston
Scientific**
Advancing science for life™

© 2023 Boston Scientific Corporation
or its affiliates. All rights reserved.

EP-1508701-AB